J Neurocrit Care.  2020 Dec;13(2):93-100. 10.18700/jnc.200023.

The good genotype for clopidogrel metabolism is associated with decreased blood viscosity in clopidogrel-treated ischemic stroke patients

• Park JH
• Han SW
• Yu HJ

• KMID: 2509938
• DOI: http://doi.org/10.18700/jnc.200023

Abstract

Background
Blood viscosity (BV) is a measurement of the intrinsic resistance of blood to flow, and high BV increases thromboembolic risk. Although laboratory documentation of clopidogrel resistance has been shown to predict an increased risk of cardiovascular events in patients with ischemic stroke, there is no evidence that cytochrome P450 2C19 (CYP2C19) polymorphisms in clopidogrel-treated patients influence BV after ischemic stroke.
Methods
Patients with ischemic stroke or transient ischemic attack within 7 days of symptom onset from April 2018 to October 2019 were included. Patients were classified into the good genotype group for clopidogrel metabolism (ultrarapid or extensive metabolizer) and poor genotype group (intermediate/unknown or poor metabolizer) based on their CYP2C19 genotype status. A scanning capillary-tube viscometer was used to assess whole BV, and patients were divided into decreased BV and increased BV groups.
Results
The final analyses included 174 patients (109 men and 65 women) with a mean age of 66.4±11.24 years. The good genotype was found in 44% of patients with decreased systolic BV (SBV) and 27% of those with increased SBV (P=0.029), suggesting that BV changes were related to the CYP2C19 genotype for clopidogrel metabolism. Binary logistic regression analysis showed that CYP2C19 genotype status (P=0.024) and baseline SBV (P<0.0001) were significantly associated with decreased BV. The good genotype for clopidogrel metabolism was associated with decreased BV in patients with ischemic stroke treated with clopidogrel.
Conclusion
The present results indicate that the effect of clopidogrel treatment on ischemic stroke prevention could be modulated not only by inhibition of platelet function but also by changes in the hemorheological profile.

Keyword

Blood viscosity; Hematocrit; Stroke

Figure

• 

  Fig. 1. Study profile. TIA, transient ischemic attack; CE, cardioembolism; SUDm, stroke of undetermined etiology (SUD), more than two causes identified; SUDi, SUD, incomplete evaluation; SOD, stroke of other determined etiology; SUDn, SUD, negative work-up; LAA, large artery atherosclerosis.

Reference

1. Furukawa K, Abumiya T, Sakai K, Hirano M, Osanai T, Shichinohe H, et al. Increased blood viscosity in ischemic stroke patients with small artery occlusion measured by an electromagnetic spinning sphere viscometer. J Stroke Cerebrovasc Dis. 2016; 25:2762–9.

2. Pop GA, Duncker DJ, Gardien M, Vranckx P, Versluis S, Hasan D, et al. The clinical significance of whole blood viscosity in (cardio)vascular medicine. Neth Heart J. 2002; 10:512–6.

3. Song SH, Kim JH, Lee JH, Yun YM, Choi DH, Kim HY. Elevated blood viscosity is associated with cerebral small vessel disease in patients with acute ischemic stroke. BMC Neurol. 2017; 17:20.

4. Kwaan HC. Role of plasma proteins in whole blood viscosity: a brief clinical review. Clin Hemorheol Microcirc. 2010; 44:167–76.

5. Mury P, Faes C, Millon A, Mura M, Renoux C, Skinner S, et al. Higher daily physical activity level is associated with lower RBC aggregation in carotid artery disease patients at high risk of stroke. Front Physiol. 2017; 8:1043.

6. Noh HJ, Seo SW, Jeong Y, Park JE, Kim GH, Noh Y, et al. Blood viscosity in subcortical vascular mild cognitive impairment with versus without cerebral amyloid burden. J Stroke Cerebrovasc Dis. 2014; 23:958–66.

7. Park JH, Kim JY, Baik JS, Park JH, Nam HS, Han SW, et al. Prior antithrombotic use is significantly associated with decreased blood viscosity within 24 hours of symptom onset in patients with acute ischemic stroke. J Neurocrit Care. 2019; 12:85–91.

8. Lim ST, Coughlan CA, Murphy SJ, Fernandez-Cadenas I, Montaner J, Thijs V, et al. Platelet function testing in transient ischaemic attack and ischaemic stroke: a comprehensive systematic review of the literature. Platelets. 2015; 26:402–12.

9. Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, et al. Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv. 2013; 6:1111–28.

10. Han SW, Kim YJ, Ahn SH, Seo WK, Yu S, Oh SH, et al. Effects of triflusal and clopidogrel on the secondary prevention of stroke based on cytochrome P450 2C19 genotyping. J Stroke. 2017; 19:356–64.

11. Ciuffetti G, Lombardini R, Pirro M, Lupattelli G, Mannarino E. Clopidogrel: hemorheological effects in subjects with subclinical atherosclerosis. Clin Hemorheol Microcirc. 2001; 25:31–9.

12. Rosenson RS, Chen Q, Najera SD, Lee ML, Cho DJ. Ticagrelor and the prevention of microvascular complications in diabetes patients with lower extremity arterial disease; rationale and design of the Hema-Kinesis trial. Cardiovasc Drugs Ther. 2018; 32:443–51.

13. Rosenson RS. Treatment with aspirin and dipyridamole is more effective than aspirin in reducing low shear blood viscosity. Microcirculation. 2008; 15:615–20.

14. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007; 6:961–9.

15. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24:35–41.

16. Cowan AQ, Cho DJ, Rosenson RS. Importance of blood rheology in the pathophysiology of atherothrombosis. Cardiovasc Drugs Ther. 2012; 26:339–48.

17. Danesh J, Collins R, Peto R, Lowe GD. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J. 2000; 21:515–20.

18. Kowal P, Marcinkowska-Gapińska A. Hemorheological changes dependent on the time from the onset of ischemic stroke. J Neurol Sci. 2007; 258:132–6.

19. Fisher M, Meiselman HJ. Hemorheological factors in cerebral ischemia. Stroke. 1991; 22:1164–9.

20. Jung LY, Lee SR, Jung JM, Kim YS, Lee SH, Rhee KS, et al. Rosuvastatin reduces blood viscosity in patients with acute coronary syndrome. Korean Circ J. 2016; 46:147–53.

21. Lee CH, Jung KH, Cho DJ, Jeong SK. Effect of warfarin versus aspirin on blood viscosity in cardioembolic stroke with atrial fibrillation: a prospective clinical trial. BMC Neurol. 2019; 19:82.

22. Stäubli M, Reinhart W, Straub PW. Blood viscosity and red cell deformability after aspirin in vivo: a double-blind controlled trial. Atherosclerosis. 1982; 41:167–70.

23. Hitosugi M, Niwa M, Takatsu A. Changes in blood viscosity by heparin and argatroban. Thromb Res. 2001; 104:371–4.

24. Dawson DL, Zheng Q, Worthy SA, Charles B, Bradley DV Jr. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication. Angiology. 2002; 53:509–20.

25. Li X, Wang Q, Xue Y, Chen J, Lv Q. Ticagrelor compared with clopidogrel increased adenosine and cyclic adenosine monophosphate plasma concentration in acute coronary syndrome patients. Basic Clin Pharmacol Toxicol. 2017; 120:610–4.

26. Alemayehu M, Kim RB, Lavi R, Gong I, D'Alfonso S, Mansell SE, et al. Effect of ticagrelor versus clopidogrel on vascular reactivity. J Am Coll Cardiol. 2017; 69:2246–8.

27. Lee JB, Lee KA, Lee KY. Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease. Yonsei Med J. 2011; 52:734–8.